Yes. Scientists have developed treatments that improve survival for Ebola virus disease caused by Zaire ebolavirus, especially when patients receive care early. But treatments that work for one ...

There’s no cure for obstructive hypertrophic cardiomyopathy (oHCM) — treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...

Theres no cure for obstructive hypertrophic cardiomyopathy (oHCM) treatments focus on symptom management and preventing complications. But the landscape is changing, and more cutting-edge therapies ...

If you have aortic stenosis and a doctor deems your condition severe, you likely will need to have your valve replaced. You may be offered a transcatheter aortic valve replacement, or TAVR, or a ...

REMOVING BARRIERS TO PSYCHEDELIC DRUGS AS POTENTIAL TREATMENT FOR SERIOUS MENTAL ILLNESS: Today, President Donald J. Trump signed an Executive Order that will accelerate access to treatments for ...

Section 1. Purpose and Policy. Policymakers and the medical field have long struggled to address the burden of suicide and serious mental illness rates in America. Today, over 14 million American ...

A new study on aortic stenosis, the most common form of heart valve disease, has identified more than 200 new genes that predispose individuals to this condition, for which no treatment currently ...

Uncover the truth about alternative medicine in cancer care. Learn how acupuncture, herbs, and supplements can complement treatment—and what to avoid. A cancer diagnosis is a challenging journey and ...

Spinal stenosis is often a chronic condition, so it may require lifelong treatment if your symptoms impact your quality of life. The severity of symptoms will range widely for each person. Researchers ...

The FDA has endorsed Cytokinetics' Myqorzo as a treatment for obstructive hypertrophic cardiomyopathy. It will compete with Bristol Myers Squibb's Camzyos in the ...

Aficamten offers a new treatment option for symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Clinical trials SEQUOIA-HCM and MAPLE-HCM showed aficamten's efficacy in improving exercise ...

SOUTH SAN FRANCISCO, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (CYTK) today announced that the U.S. Food and Drug Administration (FDA) has approved MYQORZO™ (aficamten), 5 ...